The identification and subsequent treatment of chronic cerebrospinal venous insufficiency (CCSVI) in patients with multiple sclerosis is designated as experimental / investigational and is not covered under this policy. This stance is based on a review of the available evidence, including systematic reviews and controlled observational studies, which found inconsistent associations between CCSVI and MS and concluded that the evidence is insufficient to determine that diagnostic testing or percutaneous venoplasty improves health outcomes for MS patients.

A randomized, double-blind, sham-controlled trial (PREMiSe) and multiple observational reports failed to demonstrate meaningful clinical benefit from venous angioplasty; the RCT found no statistically significant differences in venous outflow characteristics or clinical disease scores between treated and sham groups. Given the lack of demonstrated efficacy and the limitations of available studies, endovascular treatment for CCSVI is considered investigational.

All diagnoses related to this medical policy are designated experimental / investigational and therefore excluded from coverage under this policy.

Specifically, identification of CCSVI (by ultrasound, MRI, or other imaging modalities) and subsequent interventions intended to treat CCSVI in patients with multiple sclerosis are not covered because they are considered investigational.

The FDA issued an alert in May 2012 warning of potential dangers associated with unproven treatments for multiple sclerosis, noting reports of serious complications including death and the need for ongoing monitoring. Safety concerns from published case series and FDA reports have been cited in the literature and informed the policy’s risk assessment.

Available surveillance data and larger case series reported uncommon adverse events but also documented serious adverse events reported to the FDA; the literature and regulatory communications do not allow confident estimation of the rate of serious complications (eg, death, major bleeding).

Percutaneous venoplasty (balloon angioplasty with or without stent placement) for the treatment of CCSVI in MS is not supported by sufficient evidence of efficacy. A double-blind, sham-controlled RCT (published after earlier systematic reviews) enrolled small numbers of patients and found no significant improvements in venous outflow measures or clinical disease scores among treated patients compared with sham controls.

Systematic reviews and the body of observational data likewise have not validated diagnostic criteria or demonstrated clinically meaningful benefits from venoplasty; therefore, percutaneous venoplasty for CCSVI is considered investigational or not medically necessary.

Multiple systematic reviews and meta-analyses have evaluated the association between CCSVI and MS and reported heterogeneous results. Some meta-analyses found a statistically significant association, but others (including analyses excluding studies by Zamboni and collaborators) found no significant association. Recent observational studies have not supported diagnostic discrimination using Zamboni or updated criteria.

The literature includes case series, position statements, and guidance from professional societies (eg, International Society for Neurovascular Disease, Society of Interventional Radiology, NICE, European Society of Neurosonology) that caution against routine use of venous angioplasty outside of research settings. References include the original Zamboni reports, comprehensive reviews, the PREMiSe randomized trial, and society statements, which collectively do not establish venous angioplasty as an effective therapy for MS.

Chronic cerebrospinal venous insufficiency (CCSVI) is a proposed extracranial venous abnormality characterized by impaired venous drainage from the central nervous system (for example, obstruction of internal jugular or azygos veins) and defined in early reports by specific Doppler ultrasound features (the Zamboni criteria, which require ≥2 of 5 sonographic findings for diagnosis).

The hypothesis linking CCSVI to multiple sclerosis emerged from observational studies, but subsequent investigations—including systematic reviews, newer observational studies, and a randomized, sham-controlled trial—have not established a consistent association or demonstrated that treating presumed venous abnormalities improves MS-related outcomes. Given heterogeneous diagnostic reproducibility and lack of proven benefit from endovascular intervention, CCSVI remains an unproven and controversial entity in the context of MS management.